BeiGene, Ltd. (HKG:6160)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
133.50
+5.70 (4.46%)
May 13, 2025, 4:08 PM HKT

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Collaboration
30.70M
Log In
Log In
Log In
Log In
Collaboration Growth
-88.59%
Log In
Log In
Log In
Log In
Total Product
3.78B
Log In
Log In
Log In
Log In
Total Product Growth
72.59%
Log In
Log In
Log In
Log In
REVLIMID
36.03M
Log In
Log In
Log In
Log In
REVLIMID Growth
-52.61%
Log In
Log In
Log In
Log In
VIDAZA
-
Log In
Log In
Log In
Log In
VIDAZA Growth
-
Log In
Log In
Log In
Log In
ABRAXANE
-
Log In
Log In
Log In
Log In
ABRAXANE Growth
-
Log In
Log In
Log In
Log In
BRUKINSA
2.64B
Log In
Log In
Log In
Log In
BRUKINSA Growth
104.92%
Log In
Log In
Log In
Log In
Tislelizumab
620.84M
Log In
Log In
Log In
Log In
Tislelizumab Growth
15.69%
Log In
Log In
Log In
Log In
XGEVA
224.40M
Log In
Log In
Log In
Log In
XGEVA Growth
141.74%
Log In
Log In
Log In
Log In
Other Product
60.04M
Log In
Log In
Log In
Log In
Other Product Growth
38.66%
Log In
Log In
Log In
Log In
BLINCYTO
74.33M
Log In
Log In
Log In
Log In
BLINCYTO Growth
36.78%
Log In
Log In
Log In
Log In
POBEVCY
53.51M
Log In
Log In
Log In
Log In
POBEVCY Growth
-5.37%
Log In
Log In
Log In
Log In
Pamiparib
-
Log In
Log In
Log In
Log In
KYPROLIS
66.17M
Log In
Log In
Log In
Log In
KYPROLIS Growth
66.26%
Log In
Log In
Log In
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
U.S.
1.96B
Log In
Log In
Log In
Log In
U.S. Growth
73.50%
Log In
Log In
Log In
Log In
China
1.41B
Log In
Log In
Log In
Log In
China Growth
28.07%
Log In
Log In
Log In
Log In
Europe
362.63M
Log In
Log In
Log In
Log In
Europe Growth
79.51%
Log In
Log In
Log In
Log In
Rest of World
78.81M
Log In
Log In
Log In
Log In
Rest of World Growth
166.29%
Log In
Log In
Log In
Log In